Premium
Evaluation of the prognostic significance of Eosinophilia and Basophilia in a larger cohort of patients with myelodysplastic syndromes
Author(s) -
Wimazal Friedrich,
Germing Ulrich,
Kundi Michael,
Noesslinger Thomas,
Blum Sabine,
Geissler Philipp,
Baumgartner Christian,
Pfeilstoecker Michael,
Valent Peter,
Sperr Wolfgang R.
Publication year - 2010
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.25036
Subject(s) - basophilia , medicine , monocytosis , eosinophilia , myelodysplastic syndromes , international prognostic scoring system , oncology , gastroenterology , clinical significance , bone marrow
BACKGROUND: Lineage involvement and maturation arrest are considered to have prognostic significance in patients with myelodysplastic syndromes (MDS). However, although the prognostic value of neutropenia, thrombocytopenia, and monocytosis have been documented, little is known about the impact of eosinophils and basophils. METHODS: The authors examined the prognostic significance of eosinophils and basophils in 1008 patients with de novo MDS. Patients were enrolled from 3 centers of the Austrian‐German MDS Working Group and were analyzed retrospectively. Blood eosinophils and basophils were quantified by light microscopy, and their impact on survival and leukemia‐free survival was calculated by using Cox regression. RESULTS: Eosinophilia (eosinophils >350/μL) and basophilia (basophils >250/μL) predicted a significantly reduced survival ( P < .05) without having a significant impact on leukemia‐free survival. In multivariate analysis, eosinophilia and basophilia were identified as lactate dehydrogenase (LDH)‐independent prognostic variables with International Prognostic Scoring System (IPSS)‐specific impact. Although elevated LDH was identified as a major prognostic determinant in IPSS low‐risk, intermediate‐1 risk, and high‐risk subgroups, the condition “eosinophilia and/or basophilia” was identified as a superior prognostic indicator in the IPSS intermediate‐2 risk subgroup. CONCLUSIONS: The evaluation of eosinophils and basophils in patients with MDS was helpful and may complement the spectrum of variables to optimize prognostication in MDS. Cancer 2010. © 2010 American Cancer Society.